SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 28, 2015
KONINKLIJKE PHILIPS N.V.
(Exact name of registrant as specified in its charter)
Royal Philips
(Translation of registrants name into English)
The Netherlands
(Jurisdiction of incorporation or organization)
Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No þ
Name and address of person authorized to receive notices
and communications from the Securities and Exchange Commission:
M.J. van Ginneken
Koninklijke Philips N.V.
Amstelplein 2
1096 BC Amsterdam The Netherlands
This report comprises a copy of the following press release:
Philips First Quarter Results, dated April 28, 2015.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 28th of April, 2015.
KONINKLIJKE PHILIPS N.V.
/s/ M.J. van Ginneken
(General Secretary)
Philips reports Q1 comparable sales growth of 2% to EUR 5.3 billion and operational results of EUR 327 million
First-quarter highlights
| Comparable sales increase was driven by Western Europe and growth geographies |
| EBITA amounted to EUR 230 million, or 4.3% of sales, impacted by increased investments, compared to EUR 253 million, or 5.4% of sales, in Q1 2014 |
| EBITA, excluding restructuring and acquisition-related charges and other items, amounted to EUR 327 million, or 6.1% of sales, compared to EUR 304 million, or 6.5% of sales, in Q1 2014 |
| Net income amounted to EUR 100 million, compared to EUR 137 million in Q1 2014 |
| Free cash outflow amounted to EUR 443 million, compared to an outflow of EUR 431 million in Q1 2014 |
Frans van Houten, CEO:
We are encouraged by the resumption of sales growth in the first quarter of 2015, which was driven by continued strong performance in Consumer Lifestyle and positive comparable sales growth in Healthcare. We saw positive order-intake growth, despite the continued challenging Healthcare market environment. In line with our strategy to capture a larger portion of the HealthTech opportunities across the health continuum, we stepped up our investments in, among others, healthcare informatics, personal health solutions and our quality systems. We have also substantially improved our position in the growing image-guided therapy market through the acquisition of Volcano. Our investments, coupled with negative currency effects, are the main reasons for the low profitability in Healthcare in the first quarter. We also continued to make good progress in ramping up production and shipments from our Cleveland manufacturing facility, and are on track to deliver on our profit improvement plan for our diagnostic imaging business for the year.
We saw continued strong sales growth and profitability improvement in our LED business, while facing a faster decline in the conventional lighting business and underperformance in our Professional Lighting business in North America. We continue to proactively rationalize our conventional lighting operations and are confident in our conventional lighting business ability to sustain its attractive cash and profitability profile. We are pleased with the terms of the agreement to sell a majority stake in the combined LED components and Automotive lighting business to a consortium led by GO Scale Capital and expect to close this deal in the third quarter of 2015, subject to regulatory approvals.
For 2015, we expect modest comparable sales growth and we continue to be focused on driving operational performance improvements to increase the EBITA margin. Our 2016 target trajectory as announced in January remains unchanged.
Accelerate! and Separation Update
Our Accelerate! program continues to drive improvements across the organization, resulting in enhanced customer centricity and service levels, faster time-to-market for our innovations, strengthened quality and compliance systems, and better cost productivity.
In Healthcare, we were able to reduce the Ingenia MRI installation time by 60% and installation cost by 30%, by redesigning and harmonizing the end-to-end processes across the equipment installation value chain. In Consumer Lifestyle, the deployment of Lean
allowed the Male Grooming team to reduce the lead-time for development and launch of a new range of shavers by 30%. The team was able to simplify the end-to-end processes and re-use existing technology platforms. In Lighting, thanks to a faster time-to-market, a new range of basic LED lamps with a price point below USD 5.00 was successfully launched for the North American market within only four months.
We are making good progress in setting up two stand-alone, fit-for-purpose companies. We are also working on defining the optimal infrastructure and right perimeter for each business, including tax and legal structures, real estate footprint and IT systems. We have simplified the operating model and strengthened our leadership team, most recently with Rob Cascella joining us to oversee our cluster of imaging businesses. Rob was previously CEO of Hologic and brings a wealth of healthcare experience to Philips.
The transition of the Lighting business into a separate legal structure will take at least until the end of 2015, in order to be ready for the separation, which is currently intended to be effectuated through an IPO in the first half of 2016. At the same time, alternatives will continue to be carefully reviewed. Further updates will be provided over the course of the year. The company continues to estimate that separation costs will be in the range of EUR 300-400 million in 2015.
Overhead cost savings amounted to EUR 19 million in the first quarter. The Design for Excellence (DfX) program generated EUR 47 million of incremental savings in procurement in the quarter. Our End2End productivity program achieved EUR 37 million in productivity improvements.
As of March 31, 2015, Philips had completed 50% of the EUR 1.5 billion share buy-back program.
Q1 2015 Financial and Operational Overview
Healthcare
Healthcare comparable sales grew 1% year-over-year. Excluding restructuring and acquisition-related charges and other items, EBITA margin was 5.4%, down from 8.8% year-on-year, mainly driven by investments and remediation costs. Currency-comparable order intake showed low-single-digit growth, with positive performance in Europe, North America and other growth geographies partially offset by China.
We were pleased that order intake and sales returned to growth, despite a challenging healthcare environment. Performance at recently acquired Volcano was on track in the first quarter. Our ability to engage with customers on end-to-end solutions across the health continuum is increasingly proving to be a defining competitive advantage. We closed additional multi-year contracts, including a seven-year agreement with Providence Health & Services in the US and a multi-year agreement with the Kenyan Ministry of Health. We also signed a multi-year collaboration agreement with Janssen Pharmaceutica to develop a new handheld blood test.
Consumer Lifestyle
Consumer Lifestyle comparable sales increased by 10%. EBITA margin, excluding restructuring and acquisition-related charges and other items, was 11.4% of sales, compared to 10.6% of sales in Q1 2014. The increase was largely due to a combination of operational leverage and product mix, which was partially offset by negative currency effects.
Building on our strategy to deliver locally relevant innovations through strong marketing activation and increased share of online sales, our Consumer Lifestyle business continued to deliver great results and market share gains, with a particularly strong performance from our Health & Wellness portfolio.
For example, Philips is uniquely positioned to develop the Oral Health Care market. We continue to introduce exciting innovations, including the Philips Sonicare for Kids Connected toothbrush, the Sonicare AirFloss Ultra and the Adaptive Clean brush head. By making our products connected, there is future potential for data generation and integration into the cloud-based HealthSuite Digital Platform to ultimately provide total health and well-being solutions.
Lighting
Lighting (excluding the combined businesses of Lumileds and Automotive) comparable sales declined 3% year-on-year. On a nominal basis, sales increased by 9%, mainly due to positive currency effects. LED-lighting sales grew 25%, offset by a decline of 16% in overall conventional lighting sales. LED sales now represent 39% of total Lighting sales, compared to 30% in Q1 2014. EBITA margin, excluding restructuring and acquisition-related charges and other items, amounted to 8.4%, compared to 8.0% in Q1 2014. The increase was mainly driven by improved operational performance of LED and Professional Lighting Solutions, partly offset by the decline in conventional.
Quarterly report 2015 - Q1 | 2 |
We are pleased with the continued increase in LED margins, while having to manage through a faster-than-expected decline in conventional lighting and unsatisfactory overall performance in China and North America, which we are actively addressing. We are expanding our portfolio of connected lighting products for the home with innovations such as Philips Hue Phoenix, the first luminaire that provides dimmable white light. We also made further inroads with our CityTouch lighting systems, with Los Angeles, for example, adopting an advanced Philips management system that uses mobile and cloud-based technologies to control its street lighting. Philips CityTouch connected lighting management system is now used in more than 250 cities globally.
Innovation, Group & Services
Sales increased to EUR 169 million in the first quarter of 2015 from EUR 138 million in the first quarter of 2014, mainly due to higher one-time licensing revenue in IP Royalties. EBITA was a net cost of EUR 89 million, compared to a net cost of EUR 103 million in the first quarter of 2014.
To further strengthen the digital pathology business within our Healthcare Incubator, we entered into a joint development agreement with Mount Sinai Health System in New York to create a state-of-the-art digital pathology database from hundreds of thousands of tissue samples and to develop innovative algorithms to ultimately enable more personalized patient care.
In the first quarter, we completed the de-risking of the Dutch pension plan initiated in 2014, through a final payment of EUR 171 million. Consequently, we will apply defined-contribution pension accounting for the Dutch plan from the second quarter onwards. We intend to pursue further substantial pension de-risking opportunities in other geographies in the coming quarters and will report on our progress later in the year.
Conference call and audio webcast
Frans van Houten, CEO, and Ron Wirahadiraksa, CFO, will host a conference call for investors and analysts at 10:00 am CET to discuss the results. A live audio webcast of the conference call will be available on the Philips Investor Relations website.
Philips Group
4 | Press Release Q1 2015 |
Press Release Q1 2015 | 5 |
6 | Press Release Q1 2015 |
Press Release Q1 2015 | 7 |
8 | Press Release Q1 2015 |
Healthcare
Press Release Q1 2015 | 9 |
10 | Press Release Q1 2015 |
Press Release Q1 2015 | 11 |
12 | Press Release Q1 2015 |
Press Release Q1 2015 | 13 |
14 | Press Release Q1 2015 |
Additional information on the combined businesses of Lumileds and Automotive
Press Release Q1 2015 | 15 |
16 | Press Release Q1 2015 |
Press Release Q1 2015 | 17 |
18 | Press Release Q1 2015 |
Press Release Q1 2015 | 19 |
Condensed consolidated statements of income
Consolidated statements of income
in millions of EUR unless otherwise stated
Q1 2014 |
Q1 2015 |
|||||||
Sales |
4,692 | 5,339 | ||||||
Cost of sales |
(2,792 | ) | (3,223 | ) | ||||
|
|
|
|
|||||
Gross margin |
1,900 | 2,116 | ||||||
Selling expenses |
(1,166 | ) | (1,341 | ) | ||||
General and administrative expenses |
(167 | ) | (214 | ) | ||||
Research and development expenses |
(396 | ) | (436 | ) | ||||
Impairment of goodwill |
(3 | ) | | |||||
Other business income |
10 | 22 | ||||||
Other business expenses |
(6 | ) | (8 | ) | ||||
|
|
|
|
|||||
Income from operations |
172 | 139 | ||||||
Financial income |
16 | 31 | ||||||
Financial expenses |
(85 | ) | (98 | ) | ||||
|
|
|
|
|||||
Income before taxes |
103 | 72 | ||||||
Income tax expense |
(28 | ) | (31 | ) | ||||
|
|
|
|
|||||
Income after taxes |
75 | 41 | ||||||
Results relating to investments in associates |
21 | 23 | ||||||
|
|
|
|
|||||
Net income from continuing operations |
96 | 64 | ||||||
Discontinued operations - net of income tax |
41 | 36 | ||||||
|
|
|
|
|||||
Net income |
137 | 100 | ||||||
Attribution of net income for the period |
||||||||
Net income attributable to Koninklijke Philips N.V. shareholders |
138 | 99 | ||||||
Net income (loss) attributable to non-controlling interests |
(1 | ) | 1 | |||||
Earnings per common share attributable to shareholders |
||||||||
Weighted average number of common shares outstanding |
||||||||
- basic |
913,990 | 912,086 | ||||||
- diluted |
925,674 | 918,215 | ||||||
Net income attributable to shareholders per common share in EUR: |
||||||||
- basic |
0.15 | 0.11 | ||||||
- diluted |
0.15 | 0.11 |
20 | Press Release Q1 2015 |
Condensed consolidated balance sheets
Consolidated balance sheets
in millions of EUR
March 30, 2014 |
December 31, 2014 |
March 31, 2015 |
||||||||||
Non-current assets: |
||||||||||||
Property, plant and equipment |
2,709 | 2,095 | 2,344 | |||||||||
Goodwill |
6,502 | 7,158 | 8,596 | |||||||||
Intangible assets excluding goodwill |
3,171 | 3,368 | 3,985 | |||||||||
Non-current receivables |
148 | 177 | 195 | |||||||||
Investments in associates |
182 | 157 | 173 | |||||||||
Other non-current financial assets |
487 | 462 | 512 | |||||||||
Non-current derivative financial assets |
36 | 15 | 63 | |||||||||
Deferred tax assets |
1,789 | 2,460 | 2,677 | |||||||||
Other non-current assets |
57 | 69 | 89 | |||||||||
|
|
|
|
|
|
|||||||
Total non-current assets |
15,081 | 15,961 | 18,634 | |||||||||
Current assets: |
||||||||||||
Inventories |
3,449 | 3,314 | 3,916 | |||||||||
Other current financial assets |
11 | 125 | 125 | |||||||||
Other current assets |
414 | 411 | 537 | |||||||||
Current derivative financial assets |
71 | 192 | 288 | |||||||||
Income tax receivable |
70 | 140 | 118 | |||||||||
Receivables |
4,612 | 4,723 | 4,917 | |||||||||
Assets classified as held for sale |
539 | 1,613 | 1,591 | |||||||||
Cash and cash equivalents |
1,727 | 1,873 | 1,667 | |||||||||
|
|
|
|
|
|
|||||||
Total current assets |
10,893 | 12,391 | 13,159 | |||||||||
|
|
|
|
|
|
|||||||
Total assets |
25,974 | 28,352 | 31,793 | |||||||||
|
|
|
|
|
|
|||||||
Equity |
||||||||||||
Shareholders equity |
11,015 | 10,867 | 11,382 | |||||||||
Non-controlling interests |
10 | 101 | 114 | |||||||||
|
|
|
|
|
|
|||||||
Group equity |
11,025 | 10,968 | 11,496 | |||||||||
Non-current liabilities: |
||||||||||||
Long-term debt |
3,311 | 3,712 | 4,118 | |||||||||
Non-current derivative financial liabilities |
284 | 551 | 798 | |||||||||
Long-term provisions |
1,876 | 2,500 | 2,575 | |||||||||
Deferred tax liabilities |
55 | 107 | 106 | |||||||||
Other non-current liabilities |
1,503 | 1,838 | 2,066 | |||||||||
|
|
|
|
|
|
|||||||
Total non-current liabilities |
7,029 | 8,708 | 9,663 | |||||||||
Current liabilities: |
||||||||||||
Short-term debt |
406 | 392 | 1,667 | |||||||||
Current derivative financial liabilities |
75 | 306 | 590 | |||||||||
Income tax payable |
121 | 102 | 154 | |||||||||
Accounts and notes payable |
2,714 | 2,499 | 2,913 | |||||||||
Accrued liabilities |
2,518 | 2,692 | 2,778 | |||||||||
Short-term provisions |
644 | 945 | 862 | |||||||||
Liabilities directly associated with assets held for sale |
319 | 349 | 335 | |||||||||
Other current liabilities |
1,123 | 1,391 | 1,335 | |||||||||
|
|
|
|
|
|
|||||||
Total current liabilities |
7,920 | 8,676 | 10,634 | |||||||||
|
|
|
|
|
|
|||||||
Total liabilities and group equity |
25,974 | 28,352 | 31,793 |
Press Release Q1 2015 | 21 |
Condensed consolidated statements of cash flows
Consolidated statements of cash flows
in millions of EUR
Q1 2014 |
Q1 2015 |
|||||||
Cash flows from operating activities |
||||||||
Net income |
137 | 100 | ||||||
Result of discontinued operations - net of income tax |
(41 | ) | (36 | ) | ||||
Adjustments to reconcile net income to net cash provided by (used for) operating activities: |
||||||||
Depreciation, amortization, and impairments of fixed assets |
260 | 283 | ||||||
Impairment of goodwill and other non-current financial assets |
13 | | ||||||
Net gain on sale of assets |
(6 | ) | (34 | ) | ||||
Interest income |
(8 | ) | (14 | ) | ||||
Interest expense on debt, borrowings and other liabilities |
51 | 66 | ||||||
Income tax expense |
28 | 31 | ||||||
Results from investments in associates |
(21 | ) | (2 | ) | ||||
(Increase) decrease in working capital: |
(131 | ) | (18 | ) | ||||
Decrease in receivables and other current assets |
7 | 82 | ||||||
Increase in inventories |
(225 | ) | (243 | ) | ||||
Increase in accounts payable, accrued and other liabilities |
87 | 143 | ||||||
Decrease (increase) in non-current receivables, other assets and other liabilities |
(380 | ) | 42 | |||||
Decrease in provisions |
(16 | ) | (162 | ) | ||||
Other items |
25 | (365 | ) | |||||
Interest paid |
(89 | ) | (101 | ) | ||||
Interest received |
8 | 14 | ||||||
Income taxes paid |
(103 | ) | (60 | ) | ||||
|
|
|
|
|||||
Net cash used for operating activities |
(273 | ) | (256 | ) | ||||
Cash flows from investing activities |
||||||||
Net capital expenditures |
(158 | ) | (187 | ) | ||||
Purchase of intangible assets |
(11 | ) | (28 | ) | ||||
Expenditures on development assets |
(68 | ) | (72 | ) | ||||
Capital expenditures on property, plant and equipment |
(82 | ) | (92 | ) | ||||
Proceeds from sale of property, plant and equipment |
3 | 5 | ||||||
Net proceeds from (used for) derivatives and current financial assets |
2 | (37 | ) | |||||
Purchase of other non-current financial assets |
(4 | ) | | |||||
Proceeds from other non-current financial assets |
2 | 20 | ||||||
Purchase of businesses, net of cash acquired |
(17 | ) | (1,103 | ) | ||||
Net proceeds from (used for) sale of interest in businesses |
(1 | ) | 37 | |||||
|
|
|
|
|||||
Net cash used for investing activities |
(176 | ) | (1,270 | ) | ||||
Cash flows from financing activities |
||||||||
Proceeds from issuance of short-term debt |
78 | 1,192 | ||||||
Principal payments on long-term debt |
(273 | ) | (20 | ) | ||||
Proceeds from issuance of long-term debt |
14 | 18 | ||||||
Treasury shares transactions (net) |
(107 | ) | (108 | ) | ||||
|
|
|
|
|||||
Net cash (used for) provided by financing activities |
(288 | ) | 1,082 | |||||
|
|
|
|
|||||
Net cash used for continuing operations |
(737 | ) | (444 | ) | ||||
Cash flows from discontinued operations |
||||||||
Net cash provided by operating activities |
17 | 64 | ||||||
|
|
|
|
|||||
Net cash provided by discontinued operations |
17 | 64 | ||||||
|
|
|
|
|||||
Net cash used for continuing and discontinued operations |
(720 | ) | (380 | ) | ||||
|
|
|
|
|||||
Effect of change in exchange rates on cash and cash equivalents |
(18 | ) | 174 | |||||
Cash and cash equivalents at the beginning of the period |
2,465 | 1,873 | ||||||
|
|
|
|
|||||
Cash and cash equivalents at the end of the period |
1,727 | 1,667 |
For a number of reasons, principally the effects of translation differences, certain items in the statements of cash flows do not correspond to the differences between the balance sheet amounts for the respective items.
22 | Press Release Q1 2015 |
Condensed consolidated statement of changes in equity
Consolidated statement of changes in equity
in millions of EUR
common shares |
capital in |
retained earnings |
revaluation reserve |
currency translation differences |
available- for-sale |
cash flow hedges |
treasury shares at cost |
total shareholders equity |
non- controlling interests |
Group equity |
||||||||||||||||||||||||||||||||||
Balance as of December 31, 2014 |
187 | 2,181 | 8,790 | 13 | 229 | 27 | (13 | ) | (547 | ) | 10,867 | 101 | 10,968 | |||||||||||||||||||||||||||||||
Total comprehensive income |
(34 | ) | (2 | ) | 704 | 1 | (45 | ) | 624 | 1 | 625 | |||||||||||||||||||||||||||||||||
Movement non-controlling interest |
12 | 12 | ||||||||||||||||||||||||||||||||||||||||||
Purchase of treasury shares |
(22 | ) | (145 | ) | (167 | ) | (167 | ) | ||||||||||||||||||||||||||||||||||||
Re-issuance of treasury shares |
(5 | ) | (21 | ) | 61 | 35 | 35 | |||||||||||||||||||||||||||||||||||||
Share-based compensation plans |
22 | 22 | 22 | |||||||||||||||||||||||||||||||||||||||||
Income tax share-based compensation plans |
1 | 1 | 1 | |||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Total other equity movements |
18 | (43 | ) | (84 | ) | (109 | ) | 12 | (97 | ) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance as of March 31, 2015 |
187 | 2,199 | 8,713 | 11 | 933 | 28 | (58 | ) | (631 | ) | 11,382 | 114 | 11,496 |
Press Release Q1 2015 | 23 |
Pension costs and cash flows
Specification of pension costs
in millions of EUR
Q1 2014 | Q1 2015 | |||||||||||||||||||||||
Netherlands | other | total | Netherlands | other | total | |||||||||||||||||||
Defined-benefit plans |
||||||||||||||||||||||||
Pensions |
||||||||||||||||||||||||
Current service cost |
45 | 18 | 63 | 60 | 21 | 81 | ||||||||||||||||||
Interest expense |
| 14 | 14 | | 13 | 13 | ||||||||||||||||||
Interest income |
(4 | ) | | (4 | ) | (1 | ) | | (1 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
41 | 32 | 73 | 59 | 34 | 93 | ||||||||||||||||||
of which discontinued operations |
| 1 | 1 | | 1 | 1 | ||||||||||||||||||
Retiree Medical |
||||||||||||||||||||||||
Current service cost |
| | | | | | ||||||||||||||||||
Interest expense |
| 3 | 3 | | 3 | 3 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
| 3 | 3 | | 3 | 3 | ||||||||||||||||||
Defined-contribution plans |
||||||||||||||||||||||||
Cost |
2 | 37 | 39 | | 41 | 41 | ||||||||||||||||||
of which discontinued operations |
| 1 | 1 | | 1 | 1 |
Pension cash flows
in millions of EUR
Q1 2014 |
Q1 2015 |
|||||||
Contributions and benefits paid by the Company |
(478 | ) | (309 | ) |
24 | Press Release Q1 2015 |
Sectors and main countries
Sales and income from operations
in millions of EUR unless otherwise stated
Q1 2014 | Q1 2015 | |||||||||||||||||||||||
sales | income from operations | sales | income from operations | |||||||||||||||||||||
|
|
|
|
|||||||||||||||||||||
as a % of sales |
as a % of sales |
|||||||||||||||||||||||
Healthcare |
1,966 | 109 | 5.5 | % | 2,261 | 17 | 0.8 | % | ||||||||||||||||
Consumer Lifestyle |
1,016 | 96 | 9.4 | % | 1,190 | 122 | 10.3 | % | ||||||||||||||||
Lighting |
1,572 | 73 | 4.6 | % | 1,719 | 93 | 5.4 | % | ||||||||||||||||
Innovation, Group & Services |
138 | (106 | ) | | 169 | (93 | ) | | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Philips Group |
4,692 | 172 | 3.7 | % | 5,339 | 139 | 2.6 | % |
Sales, total assets and total liabilities excluding debt
in millions of EUR
sales | total assets | total liabilities excluding debt | ||||||||||||||||||||||
January to March | March 30, | March 31, | March 30, | March 31, | ||||||||||||||||||||
2014 | 2015 | 2014 | 2015 | 2014 | 2015 | |||||||||||||||||||
Healthcare |
1,966 | 2,261 | 10,512 | 13,675 | 2,983 | 4,220 | ||||||||||||||||||
Consumer Lifestyle |
1,016 | 1,190 | 2,830 | 3,250 | 1,509 | 1,652 | ||||||||||||||||||
Lighting |
1,572 | 1,719 | 6,719 | 6,303 | 2,215 | 2,354 | ||||||||||||||||||
Innovation, Group & Services |
138 | 169 | 5,374 | 6,974 | 4,206 | 5,951 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
25,435 | 30,202 | 10,913 | 14,177 | |||||||||||||||||||||
Assets and liabilities classified as held for sale |
539 | 1,591 | 319 | 335 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Philips Group |
4,692 | 5,339 | 25,974 | 31,793 | 11,232 | 14,512 |
Sales and tangible and intangible assets
in millions of EUR
sales | tangible and intangible assets1) | |||||||||||||||
January to March | March 30, | March 31, | ||||||||||||||
2014 | 2015 | 2014 | 2015 | |||||||||||||
Netherlands |
136 | 142 | 895 | 950 | ||||||||||||
United States |
1,374 | 1,627 | 7,305 | 9,693 | ||||||||||||
China |
541 | 615 | 1,043 | 1,255 | ||||||||||||
Germany |
298 | 317 | 285 | 147 | ||||||||||||
Japan |
254 | 247 | 410 | 425 | ||||||||||||
France |
192 | 186 | 77 | 50 | ||||||||||||
India |
139 | 171 | 125 | 146 | ||||||||||||
Other countries |
1,758 | 2,034 | 2,242 | 2,259 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Philips Group |
4,692 | 5,339 | 12,382 | 14,925 |
1) | Includes property, plant and equipment, goodwill, and intangible assets excluding goodwill |
Press Release Q1 2015 | 25 |
Reconciliation of non-GAAP performance measures
Certain non-GAAP financial measures are presented when discussing the Philips Groups performance. In the following tables, reconciliations to the most directly comparable IFRS measures are presented.
Sales growth composition
in %
Q1 2015 | ||||||||||||||||
comparable growth |
currency effects |
consolidation changes |
nominal growth |
|||||||||||||
2015 versus 2014 |
||||||||||||||||
Healthcare |
1.4 | 11.4 | 2.2 | 15.0 | ||||||||||||
Consumer Lifestyle |
9.8 | 7.3 | 0.0 | 17.1 | ||||||||||||
Lighting |
(2.9 | ) | 8.8 | 3.5 | 9.4 | |||||||||||
IG&S |
15.2 | 3.8 | 3.5 | 22.5 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Philips Group |
2.1 | 9.5 | 2.2 | 13.8 |
EBITA excluding restructuring and acquisition-related charges and other items to Income from operations (or EBIT)
in millions of EUR
Philips Group |
Healthcare | Consumer Lifestyle |
Lighting | Innovation, Group & Services |
||||||||||||||||
2015 |
||||||||||||||||||||
EBITA excluding restructuring and acquisition-related charges and other items |
327 | 123 | 136 | 144 | (76 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Other items |
(39 | ) | (28 | ) | (11 | ) | ||||||||||||||
Restructuring and acquisition-related charges |
(58 | ) | (30 | ) | (1 | ) | (25 | ) | (2 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
EBITA (or Adjusted income from operations) |
230 | 65 | 135 | 119 | (89 | ) | ||||||||||||||
Amortization of intangibles1) |
(91 | ) | (48 | ) | (13 | ) | (26 | ) | (4 | ) | ||||||||||
Impairment of goodwill |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Income from operations (or EBIT) |
139 | 17 | 122 | 93 | (93 | ) | ||||||||||||||
2014 |
||||||||||||||||||||
EBITA excluding restructuring and acquisition-related charges and other items |
304 | 173 | 108 | 126 | (103 | ) | ||||||||||||||
Restructuring and acquisition-related charges |
(51 | ) | (21 | ) | 0 | (30 | ) | 0 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
EBITA (or adjusted income from operations) |
253 | 152 | 108 | 96 | (103 | ) | ||||||||||||||
Amortization of intangibles1) |
(78 | ) | (42 | ) | (12 | ) | (21 | ) | (3 | ) | ||||||||||
Impairment of goodwill |
(3 | ) | (1 | ) | (2 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Income from operations (or EBIT) |
172 | 109 | 96 | 73 | (106 | ) |
1) | Excluding amortization of software and product development |
Composition of cash flows
in millions of EUR
Q1 2014 |
Q1 2015 |
|||||||
Cash flows used for operating activities |
(273 | ) | (256 | ) | ||||
Cash flows used for investing activities |
(176 | ) | (1,270 | ) | ||||
|
|
|
|
|||||
Cash flows before financing activities |
(449 | ) | (1,526 | ) | ||||
Cash flows used for operating activities |
(273 | ) | (256 | ) | ||||
Net capital expenditures: |
(158 | ) | (187 | ) | ||||
Purchase of intangible assets |
(11 | ) | (28 | ) | ||||
Expenditures on development assets |
(68 | ) | (72 | ) | ||||
Capital expenditures on property, plant and equipment |
(82 | ) | (92 | ) | ||||
Proceeds from sale of property, plant and equipment |
3 | 5 | ||||||
|
|
|
|
|||||
Free cash flows |
(431 | ) | (443 | ) |
26 | Press Release Q1 2015 |
Reconciliation of non-GAAP performance measures (continued)
Net operating capital to total assets
in millions of EUR
Philips Group | Healthcare | Consumer Lifestyle |
Lighting | IG&S | ||||||||||||||||
March 31, 2015 |
||||||||||||||||||||
Net operating capital (NOC) |
10,977 | 9,400 | 1,598 | 3,927 | (3,948 | ) | ||||||||||||||
Exclude liabilities comprised in NOC: |
||||||||||||||||||||
- payables/liabilities |
10,634 | 3,218 | 1,359 | 1,710 | 4,347 | |||||||||||||||
- intercompany accounts |
| 155 | 74 | 152 | (381 | ) | ||||||||||||||
- provisions |
3,437 | 847 | 219 | 492 | 1,879 | |||||||||||||||
Include assets not comprised in NOC: |
||||||||||||||||||||
- investments in associates |
173 | 55 | | 22 | 96 | |||||||||||||||
- other current financial assets |
125 | 125 | ||||||||||||||||||
- other non-current financial assets |
512 | 512 | ||||||||||||||||||
- deferred tax assets |
2,677 | 2,677 | ||||||||||||||||||
- cash and cash equivalents |
1,667 | 1,667 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total assets excluding assets classified as held for sale |
30,202 | 13,675 | 3,250 | 6,303 | 6,974 | |||||||||||||||
Assets classified as held for sale |
1,591 | |||||||||||||||||||
|
|
|||||||||||||||||||
Total assets |
31,793 | |||||||||||||||||||
March 30, 2014 |
||||||||||||||||||||
Net operating capital (NOC) |
10,381 | 7,443 | 1,321 | 4,484 | (2,867 | ) | ||||||||||||||
Exclude liabilities comprised in NOC: |
||||||||||||||||||||
- payables/liabilities |
8,338 | 2,551 | 1,251 | 1,671 | 2,865 | |||||||||||||||
- intercompany accounts |
| 137 | 72 | 101 | (310 | ) | ||||||||||||||
- provisions |
2,520 | 295 | 186 | 443 | 1,596 | |||||||||||||||
Include assets not comprised in NOC: |
||||||||||||||||||||
- investments in associates |
182 | 86 | | 20 | 76 | |||||||||||||||
- other current financial assets |
11 | 11 | ||||||||||||||||||
- other non-current financial assets |
487 | 487 | ||||||||||||||||||
- deferred tax assets |
1,789 | 1,789 | ||||||||||||||||||
- cash and cash equivalents |
1,727 | 1,727 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total assets excluding assets classified as held for sale |
25,435 | 10,512 | 2,830 | 6,719 | 5,374 | |||||||||||||||
Assets classified as held for sale |
539 | |||||||||||||||||||
|
|
|||||||||||||||||||
Total assets |
25,974 |
Composition of net debt to group equity
in millions of EUR unless otherwise stated
March 30, 2014 |
March 31, 2015 |
|||||||
Long-term debt |
3,311 | 4,118 | ||||||
Short-term debt |
406 | 1,667 | ||||||
|
|
|
|
|||||
Total debt |
3,717 | 5,785 | ||||||
Cash and cash equivalents |
1,727 | 1,667 | ||||||
|
|
|
|
|||||
Net debt (cash) (total debt less cash and cash equivalents) |
1,990 | 4,118 | ||||||
Shareholders equity |
11,015 | 11,382 | ||||||
Non-controlling interests |
10 | 114 | ||||||
|
|
|
|
|||||
Group equity |
11,025 | 11,496 | ||||||
Net debt and group equity |
13,015 | 15,614 | ||||||
Net debt divided by net debt and group equity (in %) |
15 | % | 26 | % | ||||
Group equity divided by net debt and group equity (in %) |
85 | % | 74 | % |
Press Release Q1 2015 | 27 |
Philips statistics
In the quarter statistics
in millions of EUR unless otherwise stated
2014 | 2015 | |||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |||||||||||||||||||
Sales |
4,692 | 4,969 | 5,194 | 6,536 | 5,339 | |||||||||||||||||||||
comparable sales growth % |
(1 | )% | (1 | )% | 0 | % | (2 | )% | 2 | % | ||||||||||||||||
Gross margin |
1,900 | 2,075 | 1,702 | 2,529 | 2,116 | |||||||||||||||||||||
as a % of sales |
40.5 | % | 41.8 | % | 32.8 | % | 38.7 | % | 39.6 | % | ||||||||||||||||
Selling expenses |
(1,166 | ) | (1,214 | ) | (1,245 | ) | (1,499 | ) | (1,341 | ) | ||||||||||||||||
as a % of sales |
(24.9 | )% | (24.4 | )% | (24.0 | )% | (22.9 | )% | (25.1 | )% | ||||||||||||||||
G&A expenses |
(167 | ) | (176 | ) | (191 | ) | (213 | ) | (214 | ) | ||||||||||||||||
as a % of sales |
(3.6 | )% | (3.5 | )% | (3.7 | )% | (3.3 | )% | (4.0 | )% | ||||||||||||||||
R&D expenses |
(396 | ) | (400 | ) | (372 | ) | (467 | ) | (436 | ) | ||||||||||||||||
as a % of sales |
(8.4 | )% | (8.0 | )% | (7.2 | )% | (7.1 | )% | (8.2 | )% | ||||||||||||||||
EBIT |
172 | 291 | (139 | ) | 162 | 139 | ||||||||||||||||||||
as a % of sales |
3.7 | % | 5.9 | % | (2.7 | )% | 2.5 | % | 2.6 | % | ||||||||||||||||
EBITA |
253 | 368 | (62 | ) | 262 | 230 | ||||||||||||||||||||
as a % of sales |
5.4 | % | 7.4 | % | (1.2 | )% | 4.0 | % | 4.3 | % | ||||||||||||||||
Net income (loss) |
137 | 243 | (103 | ) | 134 | 100 | ||||||||||||||||||||
Net income (loss) attributable to shareholders |
138 | 242 | (104 | ) | 139 | 99 | ||||||||||||||||||||
Net income (loss) - shareholders per common share in EUR - diluted |
0.15 | 0.26 | (0.11 | ) | 0.15 | 0.11 |
28 | Press Release Q1 2015 |
Year-to-date statistics in millions of EUR unless otherwise stated
2014 | 2015 | |||||||||||||||||||||||||
January- March |
January- June |
January- September |
January- December |
January- March |
January- June |
January- September |
January- December | |||||||||||||||||||
Sales |
4,692 | 9,661 | 14,855 | 21,391 | 5,339 | |||||||||||||||||||||
comparable sales growth % |
(1 | )% | (1 | )% | (1 | )% | (1 | )% | 2 | % | ||||||||||||||||
Gross margin |
1,900 | 3,975 | 5,677 | 8,206 | 2,116 | |||||||||||||||||||||
as a % of sales |
40.5 | % | 41.1 | % | 38.2 | % | 38.4 | % | 39.6 | % | ||||||||||||||||
Selling expenses |
(1,166 | ) | (2,380 | ) | (3,625 | ) | (5,124 | ) | (1,341 | ) | ||||||||||||||||
as a % of sales |
(24.9 | )% | (24.6 | )% | (24.4 | )% | (24.0 | )% | (25.1 | )% | ||||||||||||||||
G&A expenses |
(167 | ) | (343 | ) | (534 | ) | (747 | ) | (214 | ) | ||||||||||||||||
as a % of sales |
(3.6 | )% | (3.6 | )% | (3.6 | )% | (3.5 | )% | (4.0 | )% | ||||||||||||||||
R&D expenses |
(396 | ) | (796 | ) | (1,168 | ) | (1,635 | ) | (436 | ) | ||||||||||||||||
as a % sales |
(8.4 | )% | (8.2 | )% | (7.9 | )% | (7.6 | )% | (8.2 | )% | ||||||||||||||||
EBIT |
172 | 463 | 324 | 486 | 139 | |||||||||||||||||||||
as a % of sales |
3.7 | % | 4.8 | % | 2.2 | % | 2.3 | % | 2.6 | % | ||||||||||||||||
EBITA |
253 | 621 | 559 | 821 | 230 | |||||||||||||||||||||
as a % of sales |
5.4 | % | 6.4 | % | 3.8 | % | 3.8 | % | 4.3 | % | ||||||||||||||||
Net income |
137 | 380 | 277 | 411 | 100 | |||||||||||||||||||||
Net income attributable to shareholders |
138 | 380 | 276 | 415 | 99 | |||||||||||||||||||||
Net income - shareholders per common share in euros - diluted |
0.15 | 0.41 | 0.30 | 0.45 | 0.11 | |||||||||||||||||||||
Net income from continuing operations as a % of shareholders equity |
4.0 | % | 5.7 | % | 2.0 | % | 2.0 | % | 2.4 | % | ||||||||||||||||
Number of common shares outstanding (after deduction of treasury shares) at the end of period (in thousands) |
913,485 | 923,933 | 919,973 | 914,389 | 910,616 | |||||||||||||||||||||
Shareholders equity common share in EUR |
12.06 | 11.63 | 11.86 | 11.88 | 12.50 | |||||||||||||||||||||
Inventories as a % of sales#) |
14.8 | % | 15.9 | % | 17.1 | % | 15.3 | % | 17.3 | % | ||||||||||||||||
Net debt : group equity ratio |
15:85 | 18:82 | 19:81 | 17:83 | 26:74 | |||||||||||||||||||||
Net operating capital |
10,381 | 10,500 | 10,841 | 8,838 | 10,977 | |||||||||||||||||||||
Total employees |
114,268 | 112,834 | 115,261 | 113,678 | 115,970 | |||||||||||||||||||||
of which discontinued operations |
9,957 | 8,256 | 8,489 | 8,313 | 8,334 |
1) | Sales is calculated over the preceding 12 months |
2) | Inventories as a % of sales excludes inventories and sales related to acquisitions, divestments and discontinued operations |
Press Release Q1 2015 | 29 |
http://www.philips.com/investorrelations
© 2015 Koninklijke Philips N.V. All rights reserved.